X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ALRN

Closed

Aileron Therapeutics Inc

2.05
-0.06 (-2.84%)
Last Update: 07 Feb 2025 17:30:00
Yesterday: 2.11
Day's Range: 2. - 2.295
Send
When Written:
 
1.24
Aileron Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing a new class of therapeutics called stapled peptides. These peptides are designed to target intracellular protein-protein interactions, which are implicated in many diseases, including cancer and autoimmune disorders.

The company's lead product candidate, ALRN-6924, is a stapled peptide that targets the p53-MDM2/MDMX interaction, which is a key pathway involved in cancer cell growth and survival. Aileron is developing ALRN-6924 for the treatment of a variety of cancers, including acute myeloid leukemia (AML) and advanced solid tumors.

Aileron was founded in 2005 and is headquartered in Watertown, Massachusetts. The company went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol ALRN.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X